Quoin Pharmaceuticals Ltd ADR (QNRX)

$5.48 -0.52 (-8.69%)
Market Cap 3.23M
Revenue (ttm) 0.00
Net Income (ttm) -8.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 31,500
Avg Vol 247,541
Day's Range N/A - N/A
Shares Out 589,000.00
Stochastic %K 14%
Beta 1.89
Analysts Strong Sell
Price Target $156.64

Latest News on QNRX

Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign

Apr 10, 2025, 7:30 AM EDT - 10 days ago

Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign

Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient

Apr 2, 2025, 7:30 AM EDT - 18 days ago

Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient

Sphere Bio launches Cyto-Cellect Human IgG Kappa and Viability Assay Kit for efficient single-cell selection

Mar 31, 2025, 4:18 AM EDT - 21 days ago

Sphere Bio launches Cyto-Cellect Human IgG Kappa and Viability Assay Kit for efficient single-cell selection

Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases

Mar 25, 2025, 7:30 AM EDT - 26 days ago

Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases

Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Mar 13, 2025, 7:30 AM EDT - 5 weeks ago

Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications

Mar 4, 2025, 7:30 AM EST - 6 weeks ago

Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications

Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study

Feb 27, 2025, 7:30 AM EST - 7 weeks ago

Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study

Quoin Pharmaceuticals Launches First Episode of “NETHERTON NOW” Video Series to Raise Awareness for Netherton Syndrome

Feb 25, 2025, 7:30 AM EST - 7 weeks ago

Quoin Pharmaceuticals Launches First Episode of “NETHERTON NOW” Video Series to Raise Awareness for Netherton Syndrome

Quoin Pharmaceuticals Launches ‘NETHERTON NOW' Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure

Feb 4, 2025, 7:30 AM EST - 2 months ago

Quoin Pharmaceuticals Launches ‘NETHERTON NOW' Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure

Quoin Pharmaceuticals Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome

Jan 23, 2025, 8:30 AM EST - 3 months ago

Quoin Pharmaceuticals Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome

Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies

Jan 23, 2025, 5:30 AM EST - 3 months ago

Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies

Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study

Jan 6, 2025, 8:30 AM EST - 3 months ago

Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study

Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering

Dec 20, 2024, 9:20 AM EST - 4 months ago

Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering

Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study

Dec 19, 2024, 8:00 AM EST - 4 months ago

Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study

Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies

Dec 18, 2024, 8:18 AM EST - 4 months ago

Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies

Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024

Oct 31, 2024, 4:05 PM EDT - 6 months ago

Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024

Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO

Sep 9, 2024, 8:30 AM EDT - 7 months ago

Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results

Aug 8, 2024, 8:30 AM EDT - 9 months ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results

Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome

Aug 6, 2024, 5:00 AM EDT - 9 months ago

Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome

Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Aug 1, 2024, 4:10 PM EDT - 9 months ago

Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference

Jun 25, 2024, 4:05 PM EDT - 10 months ago

Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference

Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland

Jun 12, 2024, 8:00 AM EDT - 11 months ago

Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results

May 9, 2024, 8:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results

Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024

May 2, 2024, 4:10 PM EDT - 1 year ago

Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024

Quoin Pharmaceuticals, Ltd. (QNRX) Q4 2023 Earnings Call Transcript

Mar 14, 2024, 12:57 PM EDT - 1 year ago

Quoin Pharmaceuticals, Ltd. (QNRX) Q4 2023 Earnings Call Transcript

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results

Mar 13, 2024, 4:05 PM EDT - 1 year ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results

Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET

Mar 7, 2024, 4:05 PM EST - 1 year ago

Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET

Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome

Feb 14, 2024, 9:00 AM EST - 1 year ago

Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome

Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome

Dec 13, 2023, 8:30 AM EST - 1 year ago

Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome

Quoin Pharmaceuticals, Ltd. (QNRX) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 10:51 AM EST - 1 year ago

Quoin Pharmaceuticals, Ltd. (QNRX) Q3 2023 Earnings Call Transcript

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results

Nov 8, 2023, 5:46 PM EST - 1 year ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results

Quoin Pharmaceuticals Announces Third Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday November 9th at 8:30 am ET

Nov 3, 2023, 8:41 AM EDT - 1 year ago

Quoin Pharmaceuticals Announces Third Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday November 9th at 8:30 am ET

REPEAT -- Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome

Oct 24, 2023, 9:32 AM EDT - 1 year ago

REPEAT -- Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome

Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome

Oct 24, 2023, 8:28 AM EDT - 1 year ago

Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome

Quoin Pharmaceuticals, Ltd. (QNRX) Q2 2023 Earnings Call Transcript

Aug 7, 2023, 1:24 AM EDT - 1 year ago

Quoin Pharmaceuticals, Ltd. (QNRX) Q2 2023 Earnings Call Transcript

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2023 Financial Results

Aug 2, 2023, 4:45 PM EDT - 1 year ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2023 Financial Results

Quoin Pharmaceuticals Announces 50% Enrollment in Open Label Netherton Syndrome Clinical Trial

May 24, 2023, 8:15 AM EDT - 2 years ago

Quoin Pharmaceuticals Announces 50% Enrollment in Open Label Netherton Syndrome Clinical Trial

Quoin Pharmaceuticals, Ltd. (QNRX) Q1 2023 Earnings Call Transcript

May 12, 2023, 4:43 PM EDT - 2 years ago

Quoin Pharmaceuticals, Ltd. (QNRX) Q1 2023 Earnings Call Transcript

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2023 Financial Results

May 8, 2023, 5:00 PM EDT - 2 years ago

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2023 Financial Results

Quoin Pharmaceuticals Announces First Quarter 2023 Financial Results and Corporate Update Conference Call to Be Held on Tuesday, May 9, 2023 at 8:30 am ET

May 2, 2023, 8:30 AM EDT - 2 years ago

Quoin Pharmaceuticals Announces First Quarter 2023 Financial Results and Corporate Update Conference Call to Be Held on Tuesday, May 9, 2023 at 8:30 am ET

Quoin Pharmaceuticals Doses First Patient in Open Label Netherton Syndrome Clinical Trial

Mar 21, 2023, 8:30 AM EDT - 2 years ago

Quoin Pharmaceuticals Doses First Patient in Open Label Netherton Syndrome Clinical Trial

Quoin Pharmaceuticals, Ltd. (QNRX) Q4 2022 Earnings Call Transcript

Mar 9, 2023, 2:27 PM EST - 2 years ago

Quoin Pharmaceuticals, Ltd. (QNRX) Q4 2022 Earnings Call Transcript

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and Full Year 2022 Financial Results

Mar 8, 2023, 5:08 PM EST - 2 years ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and Full Year 2022 Financial Results

Quoin Pharmaceuticals Announces 2022 Corporate Update Conference Call to be held on Thursday March 9th at 8:30am ET

Mar 2, 2023, 4:05 PM EST - 2 years ago

Quoin Pharmaceuticals Announces 2022 Corporate Update Conference Call to be held on Thursday March 9th at 8:30am ET

Quoin Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

Feb 22, 2023, 8:39 AM EST - 2 years ago

Quoin Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

Quoin Pharmaceuticals Announces Dosing of First Patient in Clinical Trial in Netherton Syndrome

Dec 13, 2022, 8:30 AM EST - 2 years ago

Quoin Pharmaceuticals Announces Dosing of First Patient in Clinical Trial in Netherton Syndrome

Quoin Pharmaceuticals, Ltd. (QNRX) Q3 2022 Earnings Call Transcript

Nov 10, 2022, 2:38 PM EST - 2 years ago

Quoin Pharmaceuticals, Ltd. (QNRX) Q3 2022 Earnings Call Transcript

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2022 Financial Results

Nov 10, 2022, 8:30 AM EST - 2 years ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2022 Financial Results

Quoin Pharmaceuticals to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10th

Nov 1, 2022, 8:30 AM EDT - 2 years ago

Quoin Pharmaceuticals to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10th

Quoin Pharmaceuticals Announces Plans to Initiate a Second Clinical Trial in Netherton Syndrome Patients

Oct 18, 2022, 8:30 AM EDT - 2 years ago

Quoin Pharmaceuticals Announces Plans to Initiate a Second Clinical Trial in Netherton Syndrome Patients